Entrectinib price in 2023

Entrectinib (Entrectinib) is a targeted therapy that belongs to a class of drugs called multitarget tyrosine kinase inhibitors (TKI). It is mainly used to treat some cancers carrying specific gene mutations, especially neuroblastoma (Neuroblastoma) and ROS1 rearrangement-positive non-small cell lung cancer (ROS1-positive NSCLC) and NTRK gene fusion-positive malignant tumors.

Enrectinib interferes with the growth and spread of tumor cells by inhibiting some specific tyrosine kinases, such as ROS1, NTRK and ALK. Aberrant activation of these genes is associated with cancer development and progression. As a targeted therapy, entrectinib can more precisely intervene in these abnormal signaling pathways, thereby reducing the impact on normal cells.

This medication is usually taken by mouth and can be used under the supervision of a medical professional. The dosage and treatment plan will be determined based on the patient's specific situation, including the type of disease, genetic mutation, and the patient's health status.

Entrectinib has been launched in China, but due to its short time on the market, it has not yet been included in the medical insurance catalog. Since it has just been launched, it is difficult to purchase domestically and the price is very high. For specific prices, please consult the hospital pharmacy at that time. There are original drugs and generic drugs abroad. The original drugs abroad are mainly European versions of original drugs. The price is about 45,000 yuan. The price is relatively high and may be unaffordable for ordinary families. Generic drugs are mainly Lao generic drugs, with prices ranging from 4,000 to 8,000yuan, which are much cheaper than original drugs, and the ingredients of original drugs and generic drugs are basically the same.